Valeo Pharma (TSX:VPH) FCF Margin % : 11.68% (As of Jan. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Valeo Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Valeo Pharma's Free Cash Flow for the three months ended in Jan. 2024 was C$1.58 Mil. Valeo Pharma's Revenue for the three months ended in Jan. 2024 was C$13.54 Mil. Therefore, Valeo Pharma's FCF Margin % for the quarter that ended in Jan. 2024 was 11.68%.

As of today, Valeo Pharma's current FCF Yield % is -89.62%.

The historical rank and industry rank for Valeo Pharma's FCF Margin % or its related term are showing as below:

TSX:VPH' s FCF Margin % Range Over the Past 10 Years
Min: -194.75 Med: -89.73 Max: -15.47
Current: -15.47

During the past 7 years, the highest FCF Margin % of Valeo Pharma was -15.47%. The lowest was -194.75%. And the median was -89.73%.

TSX:VPH's FCF Margin % is ranked worse than
74.71% of 1028 companies
in the Drug Manufacturers industry
Industry Median: -0.025 vs TSX:VPH: -15.47

Valeo Pharma FCF Margin % Historical Data

The historical data trend for Valeo Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valeo Pharma FCF Margin % Chart

Valeo Pharma Annual Data

Trend

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

FCF Margin %

Get a 7-Day Free Trial

-49.45

-89.73

-116.40

-127.57

-39.41

Valeo Pharma Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
FCF Margin %	Get a 7-Day Free Trial															-85.61	-6.72	-9.73	-58.74	11.68

Competitive Comparison of Valeo Pharma's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Valeo Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valeo Pharma's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valeo Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Valeo Pharma's FCF Margin % falls into.

Valeo Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Valeo Pharma's FCF Margin for the fiscal year that ended in Oct. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Oct. 2023 )	/	Revenue (A: Oct. 2023 )
	=	-21.248	/	53.91
	=	-39.41 %

Valeo Pharma's FCF Margin for the quarter that ended in Jan. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jan. 2024 )	/	Revenue (Q: Jan. 2024 )
	=	1.581	/	13.539
	=	11.68 %

Valeo Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Valeo Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Valeo Pharma (TSX:VPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valeo Pharma Inc (TSX:VPH) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

VPHIF:USA

Address

16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9

Website

https://www.valeopharma.com

Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.

Executives

Luc Mainville

Senior Officer

Valeo Pharma (TSX:VPH) Headlines

No Headlines